Cancer Clinical Trials in Valencia, Valencia
24 recruitingValencia, Valencia, Spain
Showing 1–20 of 24 trials
Recruiting
Phase 3
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Breast CancerMetastatic Breast CancerAdvanced Breast Cancer+1 more
Olema Pharmaceuticals, Inc.510 enrolled233 locationsNCT06016738
Recruiting
Not Applicable
Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis
Lung Cancer (Diagnosis)Health Adult SubjectsPatient
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe)1,200 enrolled12 locationsNCT07465848
Recruiting
Phase 1Phase 2
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Non-small Cell Lung Cancer (NSCLC)KRAS, NRAS, HRAS-mutated NSCLCKRAS G12C-mutated Solid Tumors, Lung Cancer+2 more
Revolution Medicines, Inc.616 enrolled89 locationsNCT06162221
Recruiting
Phase 3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Metastatic Castration-resistant Prostate Cancer
Amgen675 enrolled164 locationsNCT06691984
Recruiting
Phase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Metastatic Colorectal Cancer
Amgen450 enrolled284 locationsNCT06252649
Recruiting
Phase 3
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Small Cell Lung CancerLimited Stage Small Cell Lung Cancer
Amgen400 enrolled204 locationsNCT06117774
Recruiting
Phase 3
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
Small Cell Lung CancerExtensive-stage Small-cell Lung Cancer
Amgen330 enrolled131 locationsNCT07005128
Recruiting
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Genitourinary Cancers
Spanish Oncology Genito-Urinary Group500 enrolled84 locationsNCT06724159
Recruiting
Phase 2
A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc170 enrolled88 locationsNCT05128825
Recruiting
Pathological Response After Neoadjuvant Treatment on NSCLC
Stage IIIA Non-small Cell Lung Cancer
Fundación GECP150 enrolled17 locationsNCT05167487
Recruiting
Phase 2
Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients
Limited Stage Small Cell Lung CancerThoracic NeoplasmsRespiratory Tract Neoplasms+1 more
Fundación GECP37 enrolled20 locationsNCT07242547
Recruiting
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
PDL1 Gene MutationNon-Small Cell Lung Cancer (Stage III)
Fundación GECP50 enrolled22 locationsNCT06634199
Recruiting
Phase 1
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Extensive-stage Small-cell Lung Cancer
Amgen220 enrolled30 locationsNCT06598306
Recruiting
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Non-small Cell Lung CancerStage IIIA Lung CancerStage IIIB Lung Cancer
Fundación GECP97 enrolled21 locationsNCT07153445
Recruiting
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Non-small Cell Lung Cancer MetastaticThoracic NeoplasmsStage IV Non-Small Cell Lung Cancer+3 more
Fundación GECP63 enrolled20 locationsNCT06917573
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Trajectories of Anxiety and Depression in Cancer Patients, Risk and Predictive Factors and Supportive Care; Prognostic Awareness and Shared Decision Making.
CancerDepressionAnxiety
Fundación Sociedad Española de Oncologia Médica540 enrolled18 locationsNCT07168096
Recruiting
Not Applicable
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Pancreatic CancerBiliary Tract NeoplasmsMalignant Biliary Obstruction
Hospital Universitari de Bellvitge120 enrolled10 locationsNCT06653192
Recruiting
Spanish Registry of Esophagogastric Cancer
Esophageal CancerGastric Cancer
Fundación Sociedad Española de Oncologia Médica10,000 enrolled38 locationsNCT04958720